CLDN3 and psoriasis: Patients with psoriasis typically exhibit increased intestinal permeability, with elevated serum levels of biomarkers such as Claudin-3, trimethylamine N-oxide (TMAO), and intestinal fatty acid binding protein (I-FABP), all of which are associated with compromised intestinal barrier function.